Compare · BVS vs DXCM
BVS vs DXCM
Side-by-side comparison of Bioventus Inc. (BVS) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BVS and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.85B, about 38.2x BVS ($756.0M).
- Over the past year, BVS is up 34.5% and DXCM is down 10.0% - BVS leads by 44.6 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 16 for BVS).
- DXCM has more recent analyst coverage (25 ratings vs 14 for BVS).
- Company
- Bioventus Inc.
- DexCom Inc.
- Price
- $9.05-1.52%
- $74.78-4.36%
- Market cap
- $756.0M
- $28.85B
- 1M return
- -11.23%
- +26.00%
- 1Y return
- +34.55%
- -10.02%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 16
- 26
- Recent ratings
- 14
- 25
Bioventus Inc.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BVS
- Director Bartholdson John A. converted options into 32,282 shares, increasing direct ownership by 41% to 111,902 units (SEC Form 4)
- Director Sutter Martin P converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Stalnecker Susan M converted options into 32,282 shares, increasing direct ownership by 30% to 138,239 units (SEC Form 4)
- Director Nohra Guy P converted options into 32,282 shares, increasing direct ownership by 28% to 148,892 units (SEC Form 4)
- Director Neels Guido J converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Hawkins William A converted options into 39,789 shares, increasing direct ownership by 15% to 297,640 units (SEC Form 4)
- Director Ladone Mary Kay converted options into 32,282 shares, increasing direct ownership by 41% to 111,263 units (SEC Form 4)
- Director Mcmurry-Heath Michelle converted options into 32,282 shares, increasing direct ownership by 72% to 77,279 units (SEC Form 4)
- Director Cowdy Philip G. converted options into 32,282 shares, increasing direct ownership by 276% to 43,982 units (SEC Form 4)
- Director Beyer Pat converted options into 32,282 shares, increasing direct ownership by 42% to 108,718 units (SEC Form 4)
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)